The role of interleukin-4 in the negative regulation of leukemia cell growth

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.

Original languageEnglish
Pages (from-to)205-209
Number of pages5
JournalLeukemia and Lymphoma
Volume9
Issue number3
DOIs
Publication statusPublished - Jan 1 1993

Fingerprint

Interleukin-4
Leukemia
Growth
Intercellular Signaling Peptides and Proteins
Hematologic Neoplasms
Leukemia, Myelomonocytic, Chronic
Colony-Stimulating Factors
Myeloid Leukemia
B-Cell Lymphoma
Hematopoietic Stem Cells
Multiple Myeloma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Granulocytes
Acute Myeloid Leukemia
Bacteriophages
Non-Hodgkin's Lymphoma
Interleukin-6
B-Lymphocytes
Cell Proliferation
Neoplasms

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The role of interleukin-4 in the negative regulation of leukemia cell growth. / Akashi, Koichi.

In: Leukemia and Lymphoma, Vol. 9, No. 3, 01.01.1993, p. 205-209.

Research output: Contribution to journalArticle

@article{6df1fc0babd344d1b175edacac716b97,
title = "The role of interleukin-4 in the negative regulation of leukemia cell growth",
abstract = "Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the {"}autocrine{"} production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.",
author = "Koichi Akashi",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/10428199309147371",
language = "English",
volume = "9",
pages = "205--209",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The role of interleukin-4 in the negative regulation of leukemia cell growth

AU - Akashi, Koichi

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.

AB - Interleukin-4 (IL-4), originally identified as a B-cell growth factor, has been shown to inhibit certain stages of hematopoietic stem cells. Recently, IL-4 has been recognized as a negative regulatory factor in the growth of hematologic malignancy. In myeloid leukemias, IL-4 can suppress the growth of growth factor-dependent leukemic blast cells derived from acute myelogenous leukemia (AML). IL-4 also suppresses the growth of chronic myelomonocytic leukemia cells through inhibiting the "autocrine" production of IL-6 or granulocyte/macro-phage colony-stimulating factor. In lymphoid malignancies, IL-4 can inhibit the proliferation of neoplastic cells from Ph1-positive acute lymphoblastic leukemia, non-Hodgkin's B-cell lymphoma, and multiple myeloma. Thus, IL-4 is expected to be useful as a therapeutic agent for these hematologic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0027298317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027298317&partnerID=8YFLogxK

U2 - 10.3109/10428199309147371

DO - 10.3109/10428199309147371

M3 - Article

C2 - 7682464

AN - SCOPUS:0027298317

VL - 9

SP - 205

EP - 209

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -